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With the advent of molecular biology in general, coupled
with essential completion of the human genome project,
significant progress has been made in understanding the
genetic basis of a number of genodermatoses. In fact,
mutations can now be identified in more than 300 genes,
and in many cases the correlation between the genetic
lesions and cutaneous findings are easily explainable (see
Uitto et al, 2002). However, in many cases the mutated
genes have turned out to be rather surprising, and the exact
relationship between the mutations and the cutaneous
manifestations remains unclear. The latter category includes
pseudoxanthoma elasticum (PXE; OMIM#264800), a pleio-
tropic multi-system disorder primarily affecting the skin,
eyes, and the cardiovascular system. The incidence of this
condition has been estimated to be in the range of 1 in
0.5–1  105, and it has been encountered in diverse ethnic
backgrounds.
PXE was delineated as a clinical entity, distinct from
xanthomas (hence pseudoxanthoma), over 100 years ago
(Darier, 1896). The relationship of eye findings, primarily
manifesting with angioid streaks, and the cutaneous lesions
was established by Drs. Gro¨nblad, an ophthalmologist, and
Strandberg, a dermatologist, both of Sweden, and conse-
quently, this condition is also known as the Gro¨nblad–
Standberg syndrome (McKusick, 1972). In addition to
cutaneous and ophthalmologic findings, cardiovascular
manifestations, including weakened pulses in extremities
leading to intermittent claudication, and in some cases early
myocardial infarctions or gastrointestinal hemorrhages due
to rupture of arterial blood vessels, complete the classic
presentation of this syndrome.
Early genetic observations, including increased fre-
quency of parental consanguinity, occurrence of the
disease in multiple affected siblings with normal parents,
and the rarity of the disorder in successive generations,
implied autosomal recessive inheritance. Subsequently,
however, the existence of autosomal dominant variants
was suggested. Furthermore, the genetic complexity has
been compounded by indications that obligate heterozy-
gous carriers in families with autosomal recessive forms of
PXE may show minimal manifestation of the disease.
The unifying diagnostic histopathological feature in PXE
is calcification of pleiomorphic elastic structures in the skin.
The eye findings are due to calcification of an elastin-
containing layer within the retina, so-called Bruch’s mem-
brane, and the arterial blood vessels show characteristic
calcification of the elastic fibers. In addition to calcium
deposition, there is an accumulation of a number of
extracellular matrix components, including fibronectin and
vitronectin as well as various proteoglycan/glycosaminogly-
can macromolecules, in the lesional areas of the skin
associated with elastic fibers. Based on these observations,
PXE was considered as a prototype of connective tissue
disorder with components of the elastic fibers serving as the
candidate gene/protein systems. Uniformly, however, these
candidate genes were excluded by genetic linkage analyses
as the sites of mutations.
The molecular basis of PXE began to unravel in the late
1990s when several laboratories formed a coalition put
together by PXE International, a lay advocacy organization
representing families with PXE and supporting research on
this condition (see www.pxe.org and Uitto, 2001). As a
result of these efforts, the PXE gene was mapped by
positional cloning approaches to the short arm of chromo-
some 16, and the critical interval was further narrowed to
 500 kb within the chromosomal region 16p13.1. Exam-
ination of the human genome database revealed that this
region contained four distinct genes with no apparent
relation to the extracellular matrix of connective tissue in
general or the elastic fiber system in particular. Subsequent
sequencing of the four candidate genes within the critical
PXE interval resulted in identification of pathogenetic
mutations in the ABCC6 gene, which encodes MRP6, a
member of the ATP-dependent transmembrane transporter
family of proteins.
MRP6 has three transmembrane spanning domains and
two intracellular nucleotide binding folds (NBF1 and NBF2).
The NBF domains contain conserved Walker motifs, critical
for ATP binding and for the function of the protein as a
transmembrane transporter. A surprising finding was that
the mutated gene, ABCC6, is expressed at relatively high
levels in the liver and to a lesser extent in kidneys, but only
at a very low level in tissues affected in PXE. The specific
function of MRP6 has not been delineated, but it has been
shown that it can serve as an efflux pump transporting
small molecular weight glutathione conjugates. These
observations have led to the suggestion that impaired
transport function of MRP6 results in metabolic perturba-
tions facilitating calcification of the elastic fibers, implying
that PXE is primarily a metabolic disorder (Uitto et al,
2001).Abbreviation: PXE, pseudoxanthoma elasticum
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Recent publications have reported close to 60 distinct
mutations in patients with PXE, consisting of critical
missense mutations particularly affecting the NBFs as well
as nonsense mutations or large deletions that predict the
synthesis of truncated, and presumably non-functional,
polypeptides (see Uitto et al, 2002). In this issue, Chassaing
et al (2004) report on mutation analysis in a cohort of 19
families with PXE, mostly of French ancestry (see p. 608).
Among these families, 16 different mutations were identi-
fied, nine of them being novel variants. In particular, these
investigators found that arginine at position 518 was a
recurrently mutated amino acid (either R518Q or R518X),
and the remaining novel genetic lesions consisted of
missense mutations, a nonsense mutation, a small in-frame
deletion, and two potential splicing mutations. Collectively,
the findings by Chassaing et al add to the expanding
ABCC6 mutation database in PXE.
This study, together with earlier reports, raises several
interesting issues and confirms previous observations. First,
ABCC6 appears to be the major, if not the exclusive, gene
harboring mutations in different families with PXE. Although
the overall detection rate in this study was only 77 percent,
there is no evidence of locus heterogeneity. The authors
postulate that the reasons for the lack of detection of all
putative mutations may be due to large exonic deletions,
splice–site mutations distant from the intron–exon junctions,
or mutations in the regulatory sequences of the gene,
possibilities that are not readily detectable by the mutation
detection strategy employed by these investigators.
Secondly, one of the families examined by Chassaing
et al consisted of a clinically affected mother with two
affected children. This constellation was first suggestive of
autosomal dominant inheritance, however, molecular ana-
lysis found that the affected siblings were compound
heterozygotes for two different combinations of mutations
in ABCC6, both of them having one mutation (D1238H)
possibly inherited from the clinically unaffected father, while
the accompanying mutations in trans (T1130N and 180-
1120del, respectively) were thought to be inherited from the
affected mother. This observation agrees with previous
demonstrations that in families with vertical inheritance of
PXE in two generations the clinical manifestations are due
to presence of mutations in both alleles of the affected
individuals, the pedigree structure being pseudodominant
(Ringpfeil et al, 2000)1. Thus, there is so far no molecular
evidence of an autosomal dominant form of PXE, and the
affected individuals harbor two mutations in the ABCC6
gene, consistent with an autosomal recessive inheritance
pattern. This observation clearly has implications for genetic
counseling of families at risk for recurrence of the disease.
Thirdly, PXE demonstrates considerable both intra- and
interfamilial heterogeneity. For example, in some families
the skin manifestations are prevalent with little eye involve-
ment, while in other families ophthalmologic findings and/or
cardiovascular manifestations predominate (Neldner, 1988).
Attempts to delineate genotype/phenotype correlations,
based on the known mutations in these families, have been
previously unrewarding. Similarly, in this study, no clear
genotype/phenotype correlation could be identified.
Furthermore, marked intrafamilial phenotypic variation in
one family was observed, in spite of the fact that no major
differences in nutritional, lifestyle or environmental factors,
or medical history in general could be identified. Although
environmental factors, hormonal status, diet, and cigarette
smoking have been suggested to modify the phenotypic
outcome in patients with PXE (Neldner, 1988), the role of
these factors, with the exception of smoking, is not clear.
The findings suggest perhaps that the individuals’ genetic
background and the presence of modifier genes contribute
to the overall severity of the phenotype.
Finally, identification of specific mutations in the families
provides means of presymptomatic testing in individuals at
risk for PXE and provides the basis for DNA-based prenatal
testing and pre-implantation genetic diagnosis, if desired.
The critical question concerning the pathogenesis of PXE
relates to the metabolic pathways that link the genetic
mutations in ABCC6 with the distinct phenotypes in the
target tissues. Besides being potentially a metabolic
disorder, with the postulated presence or absence of
humoral factors that influence the calcification of elastic
structures (Uitto et al, 2001), the pathology could also
involve subtle changes in the cellular microenvironment in
the affected tissues (Beck et al, 2003). Although metabolic
screening of the plasma of patients with PXE has been
unyielding (Uitto J, unpublished), recent development of
ABCC6/ ‘‘knockout’’ mice2 will undoubtedly facilitate the
understanding of the pathomechanisms of this complex,
and seemingly puzzling, disorder.
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